Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
May 04, 2018 |
referred to consumer affairs and protection |
Assembly Bill A10527
2017-2018 Legislative Session
Sponsored By
CRESPO
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
2017-A10527 (ACTIVE) - Details
2017-A10527 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 10527 I N A S S E M B L Y May 4, 2018 ___________ Introduced by M. of A. CRESPO -- read once and referred to the Committee on Consumer Affairs and Protection AN ACT to amend the general business law, in relation to the price goug- ing of pharmaceuticals THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. The general business law is amended by adding a new section 396-rrr to read as follows: § 396-RRR. PRICE GOUGING; PHARMACEUTICALS. 1. FOR THE PURPOSES OF THIS SECTION, "PHARMACEUTICALS" SHALL MEAN ANY COMPOUND MANUFACTURED FOR SALE AS A MEDICINAL DRUG. 2. NO MANUFACTURER OR WHOLESALER OF PHARMACEUTICALS SHALL SELL OR OFFER TO SELL PHARMACEUTICALS FOR AN AMOUNT WHICH REPRESENTS AN UNCON- SCIONABLY EXCESSIVE PRICE. WHETHER A PRICE IS UNCONSCIONABLY EXCESSIVE IS A QUESTION OF LAW FOR THE COURT. 3. THE COURT'S DETERMINATION THAT A VIOLATION OF THIS SECTION HAS OCCURRED SHALL BE BASED ON ANY OF THE FOLLOWING FACTORS: (A) THAT THE AMOUNT OF THE EXCESS IN PRICE IS UNCONSCIONABLY EXTREME; (B) THAT THERE WAS AN EXERCISE OF UNFAIR LEVERAGE OR UNCONSCIONABLE MEANS; OR (C) A COMBINATION OF BOTH FACTORS. 4. IN ANY COURT PROCEEDING COMMENCED PURSUANT TO THIS SECTION, PROOF THAT A VIOLATION OF THIS SECTION HAS OCCURRED SHALL INCLUDE EVIDENCE THAT: (A) THE AMOUNT CHARGED REPRESENTS A GROSS DISPARITY BETWEEN THE MARKET PRICE OF THE PHARMACEUTICAL THAT LED TO THE ACTION UNDER THIS SECTION AND THE PRICE OF THE SAME PHARMACEUTICAL OVER THE SIX MONTHS PRIOR TO THE PRICE CHANGE THAT LED TO THE ACTION UNDER THIS SECTION; OR (B) THE AMOUNT CHARGED GROSSLY EXCEEDED THE PRICE AT WHICH THE PHARMA- CEUTICALS WERE READILY OBTAINABLE BY OTHER PURCHASERS. 5. A DEFENDANT MAY REBUT A PRIMA FACIE CASE WITH EVIDENCE THAT ADDI- TIONAL COSTS NOT WITHIN THE CONTROL OF THE DEFENDANT WERE IMPOSED ON THE DEFENDANT. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.